Vanguard Capital Management
ENTA icon

Vanguard Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Vanguard Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.7M Buy
1,211,769
+33,720
+3% +$453K ﹤0.01% 2514
2026
Q1 		$14.9M Buy
+1,178,049
New +$15.8M ﹤0.01% 2504

Other funds holding ENTA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management's ENTA Position: Q2 2026 in Review

Vanguard Capital Management increased its Enanta Pharmaceuticals (ENTA) stake by 2.9% in Q2 2026, buying an estimated $453K and bringing the position to 1,211,769 shares worth $17.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2514.

Vanguard Capital Management first reported a position in ENTA in Q1 2026 and has held it in 2 quarters since. 122 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • Vanguard Capital Management held 1,211,769 shares of Enanta Pharmaceuticals worth $17.7M as of Q2 2026.
  • Vanguard Capital Management bought 33,720 Enanta Pharmaceuticals shares in Q2 2026, an estimated $453K.
  • Enanta Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2514 holding.
  • Vanguard Capital Management first reported a position in Enanta Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 122 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.